Tysabri

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The most important adverse effect of natalizumab is progressive multifocal leukoencephalopathy (PML).1 Apart from PML, there are… (More)
  • figure 1
Is this relevant?
2014
2014
Entyvio (vedolizumab), Takeda’s drug for inflammatory bowel disease (IBD), is in line to become the first integrin inhibitor to… (More)
  • table 1
Is this relevant?
Review
2012
Review
2012
INTRODUCTION Natalizumab is very effective at reducing relapses and delaying disease progression in patients with relapsing… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2009
Review
2009
Therapeutic monoclonal antibodies are potent new tools for a molecular targeted approach to modify the course of multiple… (More)
Is this relevant?
2008
2008
1061 that isn’t the problem, says ZymoGenetics chief executive Bruce Carter. Rather, it is because the acute hospitals that use… (More)
Is this relevant?
Review
2008
Review
2008
The US FDA recently approved the monoclonal antibody TYSABRI (natalizumab) for use in the treatment of adults with moderately to… (More)
Is this relevant?
2005
2005
The future of a promising treatment for multiple sclerosis (MS) is in question after two patients takinag the drug were diagnosed… (More)
Is this relevant?
2005
2005
Although the financial implications of Elan's and Biogen Idec's shock withdrawal from the market of the highly promising multiple… (More)
Is this relevant?
2005
2005
The future of several drugs for autoimmune disorders hangs in the balance after a third case of a rare neurological disorder was… (More)
Is this relevant?
2005
2005
  • Nature Reviews Drug Discovery
  • 2005
 
Is this relevant?